Nusca A, Tuccinardi D, Proscia C, et al. - Since an increased risk of thrombotic events is seen in diabetic patients with on-treatment high platelet reactivity (HPR), researchers wished to know if the detection of diabetic patients at higher risk worthy of tailored antiplatelet and/or glucose lowering strategies may be assisted by measurements of glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV). For this purpose, they examined the link between GV, HbA1c levels and platelet reactivity in patients with type 2 diabetes mellitus (DM) receiving percutaneous coronary intervention. They enrolled 35 patients (age 70 ± 9 years, 86% male, mean HbA1c 7.2 ± 1.0%) receiving clopidogrel therapy. The independent link of HbA1c with HPR was identified. Findings revealed significant correlation of glyco-metabolic state with HPR in well-controlled type 2 DM patients taking clopidogrel therapy. Those at higher thrombotic risk were detected with the help of HbA1c but the combination of GV and HbA1c offered the highest diagnostic accuracy.